tbuckley/cabot-search huggingface dataset:
How Image-Guided Pathology Can Improve the Detection of Lymph Node Metastases in Prostate Cancer
Authors: Melline G.M. Schilham, Heidi Küsters-Vandevelde, Diederik M. Somford, M. Rijpkema, Martin Gotthardt
Journal: Clinical Nuclear Medicine (2022)

Abstract Detection of lymph node (LN) metastases in prostate cancer (PCa) is pivotal for accurate staging and determining treatment options. To date, the reference standard for nodal staging is histopathological examination of all harvested surgical specimens from extended pelvic LN dissections. However, this is a labor-intensive process, and small metastatic foci can be missed due to sampling effects. With current research expanding toward using radiolabeled prostate-specific membrane antigen ligands for image-guided surgery, new opportunities arise for image-guided pathological assessment of surgical specimens. Here, we illustrate how molecular imaging can complement histopathology and improve accurate detection of LN metastases.
SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis
Authors: Tobias Boettler, Benedikt Csernalabics, Henrike Salié, Hendrik Luxenburger, Lara Wischer, Elahe Salimi Alizei, Katharina Zoldan, Laurenz Krimmel, Peter Bronsert, Marius Schwabenland, Marco Prinz, Carolin Mogler, Christoph Neumann-Haefelin, Robert Thimme, Maike Hofmann, Bertram Bengsch
Journal: Journal of Hepatology (2022)
Corrigendum to “Intracorporeal Versus Extracorporeal Robot-assisted Kidney Autotransplantation: Experience of the ERUS RAKT Working Group” [Eur Urol 2022;81(2):168–75]
Authors: Alberto Breda, Pietro Diana, Angelo Territo, Andrea Gallioli, Alberto Piana, Josep Maria Gaya, Pavel Gavrilov, Liesbeth Desender, Benjamin Van Parys, Charles Van Praet, Edward Lambert, Zine-Eddine Khene, Van Thi Dang, Nicolas Doumerc, Karel Decaestecker
Journal: European Urology (2022)
Biological and Molecular Factors Predicting Response to Adoptive Cell Therapies in Cancer
Authors: Gerardo Ferrer, Damiana Álvarez-Errico, Manel Esteller
Journal: JNCI Journal of the National Cancer Institute (2022)

Abstract Adoptive cell therapy (ACT) constitutes a major breakthrough in cancer management that has expanded in the past years due to impressive results showing durable and even curative responses for some patients with hematological malignancies. ACT leverages antigen specificity and cytotoxic mechanisms of the immune system, particularly relying on the patient’s T lymphocytes to target and eliminate malignant cells. This personalized therapeutic approach exemplifies the success of the joint effort of basic, translational, and clinical researchers that has turned the patient’s immune system into a great ally in the search for a cancer cure. ACTs are constantly improving to reach a maximum beneficial clinical response. Despite being very promising therapeutic options for certain types of cancers, mainly melanoma and hematological malignancies, these individualized treatments still present several shortcomings, including elevated costs, technical challenges, management of adverse side effects, and a limited population of responder patients. Thus, it is crucial to discover and develop reliable and robust biomarkers to specifically and sensitively pinpoint the patients that will benefit the most from ACT as well as those at higher risk of developing potentially serious toxicities. Although unique readouts of infused cell therapy success have not yet been identified, certain characteristics from the adoptive cells, the tumor, and/or the tumor microenvironment have been recognized to predict patients’ outcome on ACT. Here, we comment on the importance of biomarkers to predict ACT chances of success to maximize efficacy of treatments and increase patients’ survival.
Extracellular vesicles derived from mesenchymal stromal cells as nanotherapeutics for liver ischaemia–reperfusion injury by transferring mitochondria to modulate the formation of neutrophil extracellular traps
Authors: Tongyu Lu, Jiebin Zhang, Jianye Cai, Jiaqi Xiao, Xin Sui, Xiaofeng Yuan, Rong Li, Yang Li, Jia Yao, Guo Lv, Xiaoyan Chen, Haitian Chen, Kaining Zeng, Yasong Liu, Wenjie Chen, Guihua Chen, Yang Yang, Jun Zheng, Yingcai Zhang
Journal: Biomaterials (2022)
Use of a Bougie vs Endotracheal Tube With Stylet and Successful Intubation on the First Attempt Among Critically Ill Patients Undergoing Tracheal Intubation
Authors: Kotaro Kida, Yuki Sugimoto, Tomohiko Sato
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors
Authors: Yanling Wu, Quanxiao Li, Yu Kong, Zhi Wang, Cheng Lei, Ji Li, Lulu Ding, Chunyu Wang, Yaping Cheng, Yaozhu Wei, Yuanlin Song, Zhenlin Yang, Chao Tu, Yu Ding, Tianlei Ying
Journal: Molecular Therapy (2022)

The inefficient tumor penetration of therapeutic antibodies has hampered their effective use in treating solid tumors. Here, we report the identification of a fully human single-domain antibody (UdAb), designated as n501, targeting the oncofetal antigen 5T4. The high-resolution crystal structure indicates that n501 adopts a compact structure very similar to that of camelid nanobodies, and binds tightly to all eight leucine-rich repeats of 5T4. Furthermore, the UdAb n501 exhibits exceptionally high stability, with no apparent activity changes over 4 weeks of storage at various temperatures. Importantly, the UdAb-based antibody-drug conjugate (n501-SN38) showed much deeper tumor penetration, significantly higher tumor uptake, and faster accumulation at tumor sites than conventional IgG1-based antibody-drug conjugate (m603-SN38), resulting in improved tumor inhibition. These results highlight the potential of UdAb-based antibody-drug conjugates as a potential class of antitumor therapeutics with characteristics of high stability and strong tumor penetration for the effective treatment of solid tumors. The inefficient tumor penetration of therapeutic antibodies has hampered their effective use in treating solid tumors. Here, we report the identification of a fully human single-domain antibody (UdAb), designated as n501, targeting the oncofetal antigen 5T4. The high-resolution crystal structure indicates that n501 adopts a compact structure very similar to that of camelid nanobodies, and binds tightly to all eight leucine-rich repeats of 5T4. Furthermore, the UdAb n501 exhibits exceptionally high stability, with no apparent activity changes over 4 weeks of storage at various temperatures. Importantly, the UdAb-based antibody-drug conjugate (n501-SN38) showed much deeper tumor penetration, significantly higher tumor uptake, and faster accumulation at tumor sites than conventional IgG1-based antibody-drug conjugate (m603-SN38), resulting in improved tumor inhibition. These results highlight the potential of UdAb-based antibody-drug conjugates as a potential class of antitumor therapeutics with characteristics of high stability and strong tumor penetration for the effective treatment of solid tumors.
Corrigendum to “Defeating relapsed and refractory malignancies through a nano-enabled mitochondria-mediated respiratory inhibition and damage pathway” [Biomaterials 229 (2020) 119580]
Authors: Zhengyang Yang, Jiafeng Wang, Song Liu, Xianghui Li, Leiying Miao, Bo Yang, Chenlin Zhang, Jian He, Shichao Ai, Wenxian Guan
Journal: Biomaterials (2022)
The seasonality of cholera in sub-Saharan Africa: a statistical modelling study
Authors: Javier Perez-Saez, Justin Lessler, Elizabeth C Lee, Francisco J Luquero, Espoir Bwenge Malembaka, Flavio Finger, José Paulo Langa, Sebastian Yennan, Benjamin Zaitchik, Andrew S Azman
Journal: The Lancet Global Health (2022)

Cholera remains a major threat in sub-Saharan Africa (SSA), where some of the highest case-fatality rates are reported. Knowing in what months and where cholera tends to occur across the continent could aid in improving efforts to eliminate cholera as a public health concern. However, largely due to the absence of unified large-scale datasets, no continent-wide estimates exist. In this study, we aimed to estimate cholera seasonality across SSA and explore the correlation between hydroclimatic variables and cholera seasonality.Using the global cholera database of the Global Task Force on Cholera Control, we developed statistical models to synthesise data across spatial and temporal scales to infer the seasonality of excess (defined as incidence higher than the 2010-16 mean incidence rate) suspected cholera occurrence in SSA. We developed a Bayesian statistical model to infer the monthly risk of excess cholera at the first and second administrative levels. Seasonality patterns were then grouped into spatial clusters. Finally, we studied the association between seasonality estimates and hydroclimatic variables (mean monthly fraction of area flooded, mean monthly air temperature, and cumulative monthly precipitation).24 (71%) of the 34 countries studied had seasonal patterns of excess cholera risk, corresponding to approximately 86% of the SSA population. 12 (50%) of these 24 countries also had subnational differences in seasonality patterns, with strong differences in seasonality strength between regions. Seasonality patterns clustered into two macroregions (west Africa and the Sahel vs eastern and southern Africa), which were composed of subregional clusters with varying degrees of seasonality. Exploratory association analysis found most consistent and positive correlations between cholera seasonality and precipitation and, to a lesser extent, between cholera seasonality and temperature and flooding.Widespread cholera seasonality in SSA offers opportunities for intervention planning. Further studies are needed to study the association between cholera and climate.US National Aeronautics and Space Administration Applied Sciences Program and the Bill & Melinda Gates Foundation.
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Authors: Cristina Encinas, José-Ángel Hernandez-Rivas, Albert Oriol, Laura Rosiñol, María-Jesús Blanchard, José-María Bellón, Ramón García-Sanz, Javier de la Rubia, Ana López de la Guía, Ana Jímenez-Ubieto, Isidro Jarque, Belén Iñigo, Victoria Dourdil, Felipe de Arriba, Clara Cuéllar Pérez-Ávila, Yolanda Gonzalez, Miguel-Teodoro Hernández, Joan Bargay, Miguel Granell, Paula Rodríguez-Otero, Maialen Silvent, Carmen Cabrera, Rafael Rios, Adrián Alegre, Mercedes Gironella, Marta-Sonia Gonzalez, Anna Sureda, Antonia Sampol, Enrique M. Ocio, Isabel Krsnik, Antonio García, Aránzazu García-Mateo, Joan-Alfons Soler, Jesús Martín, José-María Arguiñano, María-Victoria Mateos, Joan Bladé, Jesús F. San-Miguel, Juan-José Lahuerta, Joaquín Martínez-López
Journal: Blood Cancer Journal (2022)

Abstract Infections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would benefit from preventive measures. We undertook a post hoc analysis of infections in four clinical trials from the Spanish Myeloma Group, involving a total of 1347 patients (847 transplant candidates). Regarding the GEM2010 &gt; 65 trial, antibiotic prophylaxis was mandatory, so we excluded it from the final analysis. The incidence of severe infection episodes within the first 6 months was 13.8%, and majority of the patients experiencing the first episode before 4 months (11.1%). 1.2% of patients died because of infections within the first 6 months (1% before 4 months). Variables associated with increased risk of severe infection in the first 4 months included serum albumin ≤30 g/L, ECOG &gt; 1, male sex, and non-IgA type MM. A simple risk score with these variables facilitated the identification of three risk groups with different probabilities of severe infection within the first 4 months: low-risk (score 0–2) 8.2%; intermediate-risk (score 3) 19.2%; and high-risk (score 4) 28.3%. Patients with intermediate/high risk could be candidates for prophylactic antibiotic therapies.
Thirteen‐month‐old girl with hyporegenerative macrocytic anemia due to <scp>Brown–Vialetto–Van</scp> Laere syndrome 2
Authors: Nibras Naami, Arndt Borkhardt, Ayami Yoshimi, Lev Grinstein, Gabriele Escherich
Journal: American Journal of Hematology (2022)

We diagnosed a 13-month-old girl with severe neurological deficits and hyporegenerative macrocytic anemiawith Brown-Vialetto-Van Laere syndrome type 2 (BVVL 2), a rare disorder of the riboflavin transporter, caused by variants in the SLC52A2 gene. Bone marrow aspiration revealed hypoplastic erythropoiesis and vacuolization of myelocytes, proerythroblasts, and micromegakaryocytes. We suggest BVVL 2 as an important differential diagnosis in hyporegenerative macrocytic anemia as rapid diagnosis and initiation of therapy are crucial for the remedy of hematological and neurological impairment.
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
Authors: Hisashi Saji, Morihito Okada, Masahiro Tsuboi, Ryu Nakajima, Kenji Suzuki, Keiju Aokage, Tadashi Aoki, Jiro Okami, Ichiro Yoshino, Hiroyuki Ito, Norihito Okumura, Masafumi Yamaguchi, Norihiko Ikeda, Masashi Wakabayashi, Kenichi Nakamura, Haruhiko Fukuda, Shinichiro Nakamura, Tetsuya Mitsudomi, Shun-Ichi Watanabe, Hisao Asamura
Journal: The Lancet (2022)
Mortality and Morbidity in Mild Primary Hyperparathyroidism: Results From a 10-Year Prospective Randomized Controlled Trial of Parathyroidectomy Versus Observation
Authors: Mikkel Pretorius, Karolina Lundstam, Ansgar Heck, Morten W. Fagerland, Kristin Godang, Charlotte Mollerup, Stine L. Fougner, Ylva Pernow, Turid Aas, Ola Hessman, Thord Rosén, Jörgen Nordenström, Svante Jansson, Mikael Hellström, Jens Bollerslev
Journal: Annals of Internal Medicine (2022)

Primary hyperparathyroidism (PHPT) is a common endocrine disorder associated with increased risk for fractures, cardiovascular disease, kidney disease, and cancer and increased mortality. In mild PHPT with modest hypercalcemia and without known morbidities, parathyroidectomy (PTX) is debated because no long-term randomized trials have been performed.To examine the effect of PTX on mild PHPT with regard to mortality (primary end point) and key morbidities (secondary end point).Prospective randomized controlled trial. (ClinicalTrials.gov: NCT00522028).Eight Scandinavian referral centers.From 1998 to 2005, 191 patients with mild PHPT were included.Ninety-five patients were randomly assigned to PTX, and 96 were assigned to observation without intervention (OBS).Date and causes of death were obtained from the Swedish and Norwegian Cause of Death Registries 10 years after randomization and after an extended observation period lasting until 2018. Morbidity events were prospectively registered annually.After 10 years, 15 patients had died (8 in the PTX group and 7 in the OBS group). Within the extended observation period, 44 deaths occurred, which were evenly distributed between groups (24 in the PTX group and 20 in the OBS group). A total of 101 morbidity events (cardiovascular events, cerebrovascular events, cancer, peripheral fractures, and renal stones) were also similarly distributed between groups (52 in the PTX group and 49 in the OBS group). During the study, a total of 16 vertebral fractures occurred in 14 patients (7 in each group).During the study period, 23 patients in the PTX group and 27 in the OBS group withdrew.Parathyroidectomy does not appear to reduce morbidity or mortality in mild PHPT. Thus, no evidence of adverse effects of observation was seen for at least a decade with respect to mortality, fractures, cancer, cardiovascular and cerebrovascular events, or renal morbidities.Swedish government, Norwegian Research Council, and South-Eastern Norway Regional Health Authority.
Antihypertensive drugs reduced risk for new-onset type 2 diabetes; effect varies by antihypertensive class
Authors: Michael Tanner
Journal: Annals of Internal Medicine (2022)

ACP Journal ClubApril 2022Antihypertensive drugs reduced risk for new-onset type 2 diabetes; effect varies by antihypertensive classMichael Tanner, MDMichael Tanner, MDNYU Grossman School of Medicine, New York, New York, USA (M.T.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/J22-0018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationNazarzadeh M, Bidel Z, Canoy D, et al. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet. 2021;398:1803-10. https://pubmed.ncbi.nlm.nih.gov/34774144Clinical Impact RatingsGIM/FP/GP: Cardiology: Endocrinology: References1. New York State Department of Health. Prediabetes. Accessed at https://health.ny.gov/diseases/conditions/diabetes/prediabetes/ on 10 Feb 2022. Google Scholar2. Centers for Disease Control and Prevention. Facts about hypertension. Accessed at www.cdc.gov/bloodpressure/facts.htm on 10 Feb 2022. Google Scholar3. Centers for Disease Control and Prevention. Prevalence of prediabetes among adults. Accessed at www.cdc.gov/diabetes/data/statistics-report/prevalence-of-prediabetes.html on 10 Feb 2022. Google Scholar4. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-104. [PMID: 30165516] Google Scholar5. Eleftheriadou I, Tsioufis C, Tsiachris D, et al. Choice of antihypertensive treatment in subjects with pre-diabetes. Is there a dream after the navigator. Curr Vasc Pharmacol. 2011;9:715-22. [PMID: 21470107] Google Scholar Author, Article, and Disclosure InformationAffiliations: NYU Grossman School of Medicine, New York, New York, USA (M.T.)Disclosures: The commentator has reported no disclosures of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=J22-0018.This article was published at Annals.org on 05 April 2022. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics April 2022Volume 175, Issue 4Page: JC44KeywordsACE inhibitorsBlood pressureClinical trialsDisclosureDrugsHbA1cHypertensionNetwork analysisSystolic pressureType 2 diabetes ePublished: 5 April 2022 Issue Published: April 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Impact of Positive Airway Pressure Therapy Adherence on Outcomes in Patients with Obstructive Sleep Apnea and Chronic Obstructive Pulmonary Disease
Authors: Kimberly L. Sterling, Jean-Louis Pépin, Walter Linde-Zwirble, Jiaming Chen, Adam V. Benjafield, Peter A. Cistulli, Kate V. Cole, Hussein Emami, Caleb Woodford, Jeff P. Armitstead, Carlos M. Nunez, Jadwiga A. Wedzicha, Atul Malhotra
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

Rationale: The co-occurrence of obstructive sleep apnea and chronic obstructive pulmonary disease, termed overlap syndrome, has a poor prognosis. However, data on positive airway pressure (PAP) treatments and their impact on outcomes and costs are lacking. Objectives: This retrospective observational study investigated the effects of PAP on health outcomes, resource usage, and costs in patients with overlap syndrome. Methods: Deidentified adjudicated claims data for patients with overlap syndrome in the United States were linked to objectively measured PAP user data. Patients were considered adherent to PAP therapy if they met Centers for Medicare and Medicaid Services criteria for eight 90-day timeframes from device setup through 2-year follow-up. Propensity score matching was used to create comparable groups of adherent and nonadherent patients. Healthcare resource usage was based on the number of doctor visits, all-cause emergency room visits, all-cause hospitalizations, and PAP equipment and supplies, and proxy costs were obtained. Measurements and Main Results: A total of 6,810 patients were included (mean age, 60.8 yr; 56% female); 2,328 were nonadherent. Compared with the year before therapy, there were significant reductions in the number of emergency room visits, hospitalizations, and severe acute exacerbations during 2 years of PAP therapy in patients who were versus were not adherent (all P < 0.001). This improvement in health status was paralleled by a significant reduction in the associated healthcare costs. Conclusions: PAP usage by patients with overlap syndrome was associated with reduced all-cause hospitalizations and emergency room visits, severe acute exacerbations, and healthcare costs.
Long-term Efficacy of Total and Partial Posterior Fundoplication to Treat Gastroesophageal Reflux Disease
Authors: Bernard Dallemagne, Silvana Perretta
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal